<DOC>
	<DOCNO>NCT01862939</DOCNO>
	<brief_summary>This randomize , placebo-controlled , 2-part , sequential , single ascend dose study . Part 1 planned 6 sequential escalation treatment group . Part 2 randomized , placebo-controlled , two-period sequential pharmacodynamic ( PD ) arm .</brief_summary>
	<brief_title>A Two-Part , Single Ascending Dose Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics DS-7309 Healthy Volunteers Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Women must nonchild bear potential , ie , either : 1 . Surgically sterile ( ie , bilateral tubal ligation removal ovary and/or uterus least 6 month prior dose ) , 2 . Naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose , follicle stimulate hormone ( FSH ) level screen ≥ 40 mIU/mL . All woman must negative serum pregnancy test screening within 48 hour dose . Able understand willing comply study requirement , willing follow study medication regimen . Subjects must give write informed consent participation study prior screen . Negative urine test drug abuse alcohol screening checkin . Negative result HIV antibody , hepatitis B surface antigen , hepatitis C antibody screen . Subjects must agree abstain alcohol , cola , tea , coffee , chocolate caffeinated drink food 2 day checkin throughout confinement . Subjects must agree abstain grapefruit/grapefruit juice Seville oranges 10 day first dose throughout study . Healthy woman childbearing potential men , 18 45 year age , inclusive . Body Mass Index ( BMI ) 19.00 32.00 kg/m2 inclusive . Good health , determine absence clinically significant deviation normal , base medical history , physical examination , laboratory report , 12lead ECG , deem Investigator , prior enrollment . Baseline ( 0 hour ) predose capillary blood glucose ≥ 70 mg/dL . Part 2 ( T2DM subject ) Women childbearing potential men , 18 55 year age , inclusive . Diagnosis type 2 diabetes mellitus minimum 3 month prior first dose . Body Mass Index ( BMI ) 19.00 40.00 kg/m2 inclusive . Subjects either : 1 . Treatment naïve antidiabetic treatment least 6 month prior screen hemoglobin A1c ( HBA1c ) value 7 % 10 % , inclusive . 2 . On metformin alone HBA1c value 7 % 9 % , inclusive , willing discontinue current metformin treatment least 2 week prior study duration study . See Section 9.10.1 monitoring 2 week washout . Female subject childbearing potential , pregnant ( base test result ) breast feed . Male subject ensure use condom spermicide dose 12 week dose . Male subject must agree donate sperm dose 12 week dose . Any history drug abuse . History alcohol addiction 2 year prior Day 1 . History current evidence , determine Investigator , psychiatric emotional problem would invalidate give informed consent limit ability subject comply study requirement . History current alcoholic nonalcoholic liver disease liver steatosis . History neuropathy . Subjects QTcF interval duration &gt; 450 msec obtain ECG take screening , least 10 minute quiet rest supine position . Subjects family history long QT syndrome . Subjects history arrhythmia . Significant blood donation significant blood loss within 56 day Day 1 . Plasma donation within 7 day Day 1 . Participation another investigational new drug research study within 30 day Day 1 . Use tobacco product nicotinecontaining product ( include smoke cessation aid , gum patch ) within 6 month Day 1 . Relationship subject Investigator , subinvestigator , pharmacist , study coordinator , staff directly involve conduct study , employment Sponsor contract research organization participate study . Familial relationship subject subject previously currently enrol study . Screening laboratory value outside range normal value deem clinically significant Investigator . Liver function test ( AST , ALT , total bilirubin , lactate dehydrogenase [ LDH ] ) must ULN . If subject nonclinically significant high abnormal read one liver function test screen lab test , test may repeat . If lab test result normal repeat test , he/she may enrol provide Day 1 lab test result also normal . Hemoglobin level low limit normal clinical laboratory 's reference range screen visit . Enrollment prior dose cohort study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>